2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

4:30PM-6:00PM: Abstract Number: 949

Sequence Homology and Immune Reactivity between T Cell Epitopes of Related Gut Microbes and Two Novel Autoantigens Provide a Link between Microbial and Host Immunity in Patients with Rheumatoid Arthritis

T Cell Biology and Targets in Autoimmune Disease

4:30PM-6:00PM: Abstract Number: 952

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Lymphocyte Homeostasis In Vivo and Its Deficiency Associates with Lymphopenia in SLE Patients

T Cell Biology and Targets in Autoimmune Disease

4:30PM-6:00PM: Abstract Number: 939

Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients

Pediatric Rheumatology – Pathogenesis and Genetics

4:30PM-6:00PM: Abstract Number: 943

The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics I

4:30PM-6:00PM: Abstract Number: 910

Training Adult Rheumatology Fellows in Young Adult Transition and Transfer Skills

Education

4:30PM-6:00PM: Abstract Number: 937

Treatment Response in Polyarticular JIA Is Associated with Transcriptional Changes and Chromatin Reorganization in CD4+ T Cells

Pediatric Rheumatology – Pathogenesis and Genetics

4:30PM-6:00PM: Abstract Number: 909

Two-Year Impact of a Continuing Professional Education Program to Train Primary Care Providers to Perform Arthrocentesis

Education

4:30PM-6:00PM: Abstract Number: 929

Variation in SLE-Related Pain – a Seven Year Follow-up Study

ARHP Clinical Practice/Patient Care/Health Services Research

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].